On March 29, 2026, Insilico Medicine formed a significant partnership with Eli Lilly. The partnership, which is worth up to $2.75 billion, focuses on early-stage drug development using artificial intelligence.
The agreement gives Eli Lilly exclusive worldwide rights to develop, manufacture, and commercialize a list of oral drugs developed by Insilico Medicine. These drugs are in the preclinical development stage, meaning they have not yet been tested in humans.
The two companies are also collaborating to work on new research projects. Eli Lilly will select the biological targets, and Insilico Medicine will use its pharma.AI platform to develop drug candidates. Eli Lilly will use its experience to advance the drug candidates through
A Multi-Billion Dollar Bet on Generative AI Drug Discovery
The partnership will be working in some key disease areas. These include fibrosis, cancer, immune system diseases, and metabolic diseases. These are areas with long development periods and high failure rates. They are therefore suitable for AI-based solutions.
The agreement is structured in such a way that it reflects the early stage of these assets. Insilico will receive $115 million in an upfront payment. This will provide it with immediate cash to support its ongoing research.
In addition to this, Insilico can also receive up to $2.75 billion in milestone payments. These payments are dependent on the success of the compounds in their development, approval, and commercialization. However, if some of these compounds fail during their development, then the amount paid to Insilico will be lower.
Insilico will also receive royalties from sales. This means it will benefit from the success of any of these compounds in the future.
Such an arrangement is also common in biotech partnerships. It minimizes risks for both parties. Lilly won’t be forced to pay the full sum upfront, and Insilico will retain the potential to reap more profits if its technology performs exceptionally.
This partnership is an example of the changing face of the pharmaceutical sector. The discovery of drugs is always a long and costly process. It may take more than a decade and billions of dollars to develop a single drug.
AI is changing the face of drug discovery. It is now possible to find potential drugs more quickly and accurately using machine learning models. It may save time and money in the initial stages of drug discovery.
Insilico has put significant emphasis on generative AI in drug discovery. It uses AI to design brand-new molecules from scratch, unlike other AI systems that rely on screening molecules already in existence.
How the Lilly-Insilico Alliance is Redefining AI Drug Development
For Lilly, it means gaining access to this technology without having to build it from scratch. They can simply plug in Insilico’s technology into their existing R&D pipeline and evaluate its effect.
This is not the first time these companies have partnered. In 2023, they signed a software licensing agreement. This allowed Lilly to utilize parts of Insilico’s AI platform.
In November 2025, their partnership took another turn with the signing of a research partnership worth over $100 million. This agreement concentrated on the early discovery aspect of things.
The latest agreement, worth $2.75 billion, is the next step in their partnership. They are moving beyond software and research into actual drug development and commercialization. This is evidence of Lilly’s trust in Insilico’s technology and its ability to deliver viable drugs.
In the past few years, Insilico has experienced rapid growth. In December 2025, the company went public on the Hong Kong Stock Exchange under stock code 3696. Its focus on AI-based drug discovery has generated significant interest among both investors and pharmaceutical companies.
The company operates throughout the entire drug discovery process. This includes target identification, molecule development, and early validation. Its aim is to speed up the process and increase the probability of success at each stage.
The Catalyst of Co-Discovery, Bridging AI and Big Pharma
Such a deal is beneficial in two ways: funding and validation. Pharmaceutical firms are generally risk-averse. However, when they are willing to make long-term commitments, they are essentially showing their faith in the technology.
The success of the collaboration depends on its execution. Preclinical trials are inherently risky, and many of the drugs may not pass the test. Only a few may be able to make their way to the market.
However, the size of the deal indicates the value that pharma firms are willing to put into AI. If even a few of the programs are able to succeed, the deal would be worthwhile for both parties.
This deal is important for Lilly because they are gaining another engine to power their drug pipeline. For Insilico, the deal is essential because they are now able to deliver their AI-based drugs to the masses.
The deal is indicative of the larger trends in the industry. AI is no longer considered an experimental part of the
